黑色素瘤的诊断研究进展
Advances in Melanoma Diagnosis Research
DOI: 10.12677/acm.2026.163794, PDF,   
作者: 兰寒意:温州大学生命与环境科学学院,浙江 温州
关键词: 黑色素瘤组织诊断人工智能分子诊断Melanoma Histological Diagnosis Artificial Intelligence Molecular Diagnostics
摘要: 皮肤黑色素瘤是最严重的皮肤癌类型。深入理解黑色素瘤发生与发展的复杂生物学过程对推进患者诊疗至关重要。基于黑色素瘤较差的预后性,黑色素瘤诊断的新兴技术正在发生转变,旨在提升诊断准确性、预测疾病进展并改善预后。形态学临床病理分类预计将被更精确的分子分类所取代。随着经过验证、便捷且具有成本效益的分子检测方法的出现,分子诊断将在黑色素瘤的临床与组织学诊断中发挥更大作用。人工智能辅助的临床与组织学诊断预计将使这一过程更趋简化和高效。本文概述了黑色素瘤在诊断方面的最新进展。为深入理解当前治疗策略及新兴技术原理奠定基础,帮助临床医生把握黑色素瘤以提升临床决策水平。
Abstract: Cutaneous melanoma is the most aggressive type of skin cancer. An in-depth understanding of the complex biological processes underlying the occurrence and progression of melanoma is crucial for advancing the diagnosis and treatment of patients. Given the poor prognosis of melanoma, emerging technologies for melanoma diagnosis are undergoing transformations aimed at improving diagnostic accuracy, predicting disease progression, and enhancing prognosis. Morphological clinicopathological classification is expected to be replaced by more precise molecular classification. With the advent of validated, convenient, and cost-effective molecular detection methods, molecular diagnosis will play an increasingly important role in the clinical and histological diagnosis of melanoma. Artificial intelligence-assisted clinical and histological diagnosis is anticipated to simplify and optimize this process. This review summarizes the latest advances in melanoma diagnosis, laying a foundation for in-depth comprehension of current therapeutic strategies and the principles of emerging technologies, and helping clinicians grasp the key points of melanoma to improve clinical decision-making.
文章引用:兰寒意. 黑色素瘤的诊断研究进展[J]. 临床医学进展, 2026, 16(3): 317-323. https://doi.org/10.12677/acm.2026.163794

参考文献

[1] Nowowiejska, J., Ordon, A.J., Purpurowicz, P., Argenziano, G. and Piccolo, V. (2025) Many Faces of Melanoma: A Comparison between Cutaneous, Mucosal, Acral, Nail, and Ocular Malignancy. Pigment Cell & Melanoma Research, 38, e70051. [Google Scholar] [CrossRef] [PubMed]
[2] Lu, C., Lin, T., Mukundan, A., Karmakar, R., Chandrasekar, A., Chang, W., et al. (2025) Skin Cancer: Epidemiology, Screening and Clinical Features of Acral Lentiginous Melanoma (ALM), Melanoma in Situ (MIS), Nodular Melanoma (NM) and Superficial Spreading Melanoma (SSM). Journal of Cancer, 16, 3972-3990. [Google Scholar] [CrossRef
[3] Nwafor, J.N., Torere, B.E., Agu, E., Kadiku, L., Ogunyemi, T., Akinsanya, P.A., et al. (2023) The Role of Biomarkers in the Diagnosis and Prognosis of Different Stages of Melanoma. Cureus, 15, e38693. [Google Scholar] [CrossRef] [PubMed]
[4] Ferreira, I. and Brenn, T. (2025) Primary Cutaneous Dedifferentiated and Undifferentiated Melanoma. Seminars in Diagnostic Pathology, 42, Article ID: 150937. [Google Scholar] [CrossRef] [PubMed]
[5] Waseh, S. and Lee, J.B. (2023) Advances in Melanoma: Epidemiology, Diagnosis, and Prognosis. Frontiers in Medicine, 10, Article 1268479. [Google Scholar] [CrossRef] [PubMed]
[6] Wang, M., Zhao, J., Tang, M., Li, M., Zhao, H., Li, Z., et al. (2025) Cell Death Modalities in Therapy of Melanoma. International Journal of Molecular Sciences, 26, Article 3475. [Google Scholar] [CrossRef] [PubMed]
[7] Rosenberg, A., DeBusk, L., Shah, M., Burshtein, J., Zakria, D. and Rigel, D. (2025) Updated Techniques for Melanoma Diagnosis. Dermatologic Clinics, 43, 433-442. [Google Scholar] [CrossRef] [PubMed]
[8] Caraviello, C., Nazzaro, G., Tavoletti, G., Boggio, F., Denaro, N., Murgia, G., et al. (2025) Melanoma Skin Cancer: A Comprehensive Review of Current Knowledge. Cancers, 17, Article 2920. [Google Scholar] [CrossRef
[9] Connor, C., Carr, Q.L., Sweazy, A., McMasters, K. and Hao, H. (2025) Clinical Approaches for the Management of Skin Cancer: A Review of Current Progress in Diagnosis, Treatment, and Prognosis for Patients with Melanoma. Cancers, 17, Article 707. [Google Scholar] [CrossRef] [PubMed]
[10] Jurakić Tončić, R., Vasari, L., Štulhofer Buzina, D., Ledić Drvar, D., Petković, M. and Čeović, R. (2024) The Role of Digital Dermoscopy and Follow-Up in the Detection of Amelanotic/Hypomelanotic Melanoma in a Group of High-Risk Patients—Is It Useful? Life, 14, Article 1200. [Google Scholar] [CrossRef] [PubMed]
[11] Qasim, H., Abu Shugaer, M., Khattab, K., Leoni, M.L.G. and Varrassi, G. (2025) Histopathological Subtypes of Cutaneous Melanoma: Prognostic and Molecular Implications. Cureus, 17, e90670. [Google Scholar] [CrossRef
[12] Waqar, S., George, S., Jean-Baptiste, W., Yusuf Ali, A., Inyang, B., Koshy, F.S., et al. (2022) Recognizing Histopathological Simulators of Melanoma to Avoid Misdiagnosis. Cureus, 14, e26127. [Google Scholar] [CrossRef] [PubMed]
[13] Georgescu, S.R., Mitran, C.I., Mitran, M.I., Matei, C., Constantin, C., Neagu, M., et al. (2022) Apprising Diagnostic and Prognostic Biomarkers in Cutaneous Melanoma—Persistent Updating. Journal of Personalized Medicine, 12, Article 1506. [Google Scholar] [CrossRef] [PubMed]
[14] Huang, C., Lau, T.W. and Smoller, B.R. (2024) Diagnosing Cutaneous Melanocytic Tumors in the Molecular Era: Updates and Review of Literature. Dermatopathology, 11, 26-51. [Google Scholar] [CrossRef] [PubMed]
[15] Venturi, F., Veronesi, G., Gualandi, A., Magnaterra, E., Scotti, B., Sotiri, I., et al. (2025) From Slide to Insight: The Emerging Alliance of Digital Pathology and AI in Melanoma Diagnostics. Cancers, 17, Article 3696. [Google Scholar] [CrossRef
[16] Grant, S.R., Andrew, T.W., Alvarez, E.V., Huss, W.J. and Paragh, G. (2022) Diagnostic and Prognostic Deep Learning Applications for Histological Assessment of Cutaneous Melanoma. Cancers, 14, Article 6231. [Google Scholar] [CrossRef] [PubMed]
[17] Naseri, H. and Safaei, A.A. (2025) Diagnosis and Prognosis of Melanoma from Dermoscopy Images Using Machine Learning and Deep Learning: A Systematic Literature Review. BMC Cancer, 25, Article No. 75. [Google Scholar] [CrossRef] [PubMed]
[18] Yee, J., Rosendahl, C. and Aoude, L.G. (2023) The Role of Artificial Intelligence and Convolutional Neural Networks in the Management of Melanoma: A Clinical, Pathological, and Radiological Perspective. Melanoma Research, 34, 96-104. [Google Scholar] [CrossRef] [PubMed]
[19] Kumar, Y., Koul, A., Singla, R. and Ijaz, M.F. (2022) Artificial Intelligence in Disease Diagnosis: A Systematic Literature Review, Synthesizing Framework and Future Research Agenda. Journal of Ambient Intelligence and Humanized Computing, 14, 8459-8486. [Google Scholar] [CrossRef] [PubMed]
[20] Gopal, J., Zhou, A.E., Marghoob, A.A., Gronbeck, C. and Grant-Kels, J.M. (2025) The State of Artificial Intelligence-Enabled Skin Cancer Diagnostics: Why Are There Two Spectroscopy Devices Available Yet No Imaging Devices? Clinics in Dermatology, 43, 687-689. [Google Scholar] [CrossRef] [PubMed]
[21] Nahm, W.J., Sohail, N., Burshtein, J., Goldust, M. and Tsoukas, M. (2025) Artificial Intelligence in Dermatology: A Comprehensive Review of Approved Applications, Clinical Implementation, and Future Directions. International Journal of Dermatology, 64, 1568-1583. [Google Scholar] [CrossRef] [PubMed]
[22] Stiff, K.M., Franklin, M.J., Zhou, Y., Madabhushi, A. and Knackstedt, T.J. (2022) Artificial Intelligence and Melanoma: A Comprehensive Review of Clinical, Dermoscopic, and Histologic Applications. Pigment Cell & Melanoma Research, 35, 203-211. [Google Scholar] [CrossRef] [PubMed]
[23] Andea, A.A. (2021) Molecular Testing for Melanocytic Tumors: A Practical Update. Histopathology, 80, 150-165. [Google Scholar] [CrossRef] [PubMed]
[24] Dhanyamraju, P.K., Rotimi, S., Bhattacharya, P. and Patel, T.N. (2022) Revisiting the Melanomagenic Pathways and Current Therapeutic Approaches. Molecular Biology Reports, 49, 9651-9671. [Google Scholar] [CrossRef] [PubMed]
[25] Sun, J., Karasaki, K.M. and Farma, J.M. (2024) The Use of Gene Expression Profiling and Biomarkers in Melanoma Diagnosis and Predicting Recurrence: Implications for Surveillance and Treatment. Cancers, 16, Article 583. [Google Scholar] [CrossRef] [PubMed]
[26] King, A.D., Deirawan, H., Klein, P.A., Dasgeb, B., Dumur, C.I. and Mehregan, D.R. (2023) Next-Generation Sequencing in Dermatology. Frontiers in Medicine, 10, Article 1218404. [Google Scholar] [CrossRef] [PubMed]
[27] Shojiguchi, N., Takai, S. and Arai, E. (2022) Hyperplastic Melanocytes with Chromosomal Aberrations in Surrounding Skin of Subungual Melanoma: Fluorescence in Situ Hybridisation Analysis Using Whole‐Slide Digital Imaging. Histopathology, 81, 808-817. [Google Scholar] [CrossRef] [PubMed]
[28] Mirek, J., Bal, W. and Olbryt, M. (2024) Melanoma Genomics—Will We Go Beyond BRAF in Clinics? Journal of Cancer Research and Clinical Oncology, 150, Article No. 433. [Google Scholar] [CrossRef] [PubMed]
[29] Teh, R., Azimi, A., Pupo, G.M., Ali, M., Mann, G.J. and Fernández‐Peñas, P. (2022) Genomic and Proteomic Findings in Early Melanoma and Opportunities for Early Diagnosis. Experimental Dermatology, 32, 104-116. [Google Scholar] [CrossRef] [PubMed]
[30] Lopez de Rodas, M., Villalba-Esparza, M., Sanmamed, M.F., Chen, L., Rimm, D.L. and Schalper, K.A. (2025) Biological and Clinical Significance of Tumour-Infiltrating Lymphocytes in the Era of Immunotherapy: A Multidimensional Approach. Nature Reviews Clinical Oncology, 22, 163-181. [Google Scholar] [CrossRef] [PubMed]
[31] Xu, J., Mu, S., Wang, Y., Yu, S. and Wang, Z. (2024) Recent Advances in Immunotherapy and Its Combination Therapies for Advanced Melanoma: A Review. Frontiers in Oncology, 14, Article 1400193. [Google Scholar] [CrossRef] [PubMed]
[32] Park, Y., Kim, M.J., Choi, Y., Kim, N.H., Kim, L., Hong, S.P.D., et al. (2022) Role of Mass Spectrometry-Based Serum Proteomics Signatures in Predicting Clinical Outcomes and Toxicity in Patients with Cancer Treated with Immunotherapy. Journal for ImmunoTherapy of Cancer, 10, e003566. [Google Scholar] [CrossRef] [PubMed]
[33] Hagyousif, Y.A., Sharaf, B.M., Zenati, R.A., El-Huneidi, W., Bustanji, Y., Abu-Gharbieh, E., et al. (2023) Skin Cancer Metabolic Profile Assessed by Different Analytical Platforms. International Journal of Molecular Sciences, 24, Article 1604. [Google Scholar] [CrossRef] [PubMed]
[34] Guedes, J., Woldmar, N., Szasz, A.M., Wieslander, E., Pawłowski, K., Horvatovich, P., et al. (2025) A Perspective on Integrating Digital Pathology, Proteomics, Clinical Data and AI Analytics in Cancer Research. Journal of Proteomics, 320, Article ID: 105493. [Google Scholar] [CrossRef] [PubMed]
[35] Ostojewska, J., Wieczorek, I., Pachciński, O., et al. (2023) Detecting Undetectable-Epidemiology, Etiology, and Diagnosis of Carcinoma of Unknown Primary-Systematic Review. Folia Medica Cracoviensia, 63, 19-37.
[36] Lin, A., Sahun, M., Biscop, E., Verswyvel, H., De Waele, J., De Backer, J., et al. (2023) Acquired Non-Thermal Plasma Resistance Mediates a Shift Towards Aerobic Glycolysis and Ferroptotic Cell Death in Melanoma. Drug Resistance Updates, 67, Article ID: 100914. [Google Scholar] [CrossRef] [PubMed]
[37] Sutopo, N.C., Kim, J.H. and Cho, J.Y. (2023) Role of Histone Methylation in Skin Cancers: Histone Methylation-Modifying Enzymes as a New Class of Targets for Skin Cancer Treatment. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, 1878, Article ID: 188865. [Google Scholar] [CrossRef] [PubMed]
[38] Cassalia, F., Danese, A., Tudurachi, I., Federico, S., Zambello, A., Guidotti, A., et al. (2024) PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer. International Journal of Molecular Sciences, 25, Article 1582. [Google Scholar] [CrossRef] [PubMed]
[39] Marushchak, O., Yakubov, R., Yakubov, R., et al. (2023) New Technologies in Diagnosis and Prognosis of Melanocytic Lesions. The Journal of Clinical and Aesthetic Dermatology, 16, 44-49.
[40] Slusher, N., Jones, N. and Nonaka, T. (2024) Liquid Biopsy for Diagnostic and Prognostic Evaluation of Melanoma. Frontiers in Cell and Developmental Biology, 12, Article 1420360. [Google Scholar] [CrossRef] [PubMed]
[41] Durgham, R.A., Nassar, S.I., Gun, R., Nguyen, S.A., Asarkar, A.A. and Nathan, C.O. (2024) The Prognostic Value of the 31-Gene Expression Profile Test in Cutaneous Melanoma: A Systematic Review and Meta-Analysis. Cancers, 16, 3714. [Google Scholar] [CrossRef] [PubMed]
[42] Swetter, S.M., Thompson, J.A., Albertini, M.R., Barker, C.A., Baumgartner, J., Boland, G., et al. (2021) NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. Journal of the National Comprehensive Cancer Network, 19, 364-376. [Google Scholar] [CrossRef] [PubMed]
[43] Johnson, D.B., Swetter, S.M., Salama, A.K.S. and Wuthrick, E. (2021) Cutaneous Melanoma: Management of Melanoma Brain Metastases and Molecular Testing. Journal of the National Comprehensive Cancer Network, 19, 644-647. [Google Scholar] [CrossRef
[44] Yeh, I. (2022) Update on Classification of Melanocytic Tumors and the Role of Immunohistochemistry and Molecular Techniques. Seminars in Diagnostic Pathology, 39, 248-256. [Google Scholar] [CrossRef] [PubMed]
[45] Kim, H.J. and Kim, Y.H. (2024) Molecular Frontiers in Melanoma: Pathogenesis, Diagnosis, and Therapeutic Advances. International Journal of Molecular Sciences, 25, Article 2984. [Google Scholar] [CrossRef] [PubMed]
[46] Caraban, B.M., Aschie, M., Deacu, M., Cozaru, G.C., Pundiche, M.B., Orasanu, C.I., et al. (2024) A Narrative Review of Current Knowledge on Cutaneous Melanoma. Clinics and Practice, 14, 214-241. [Google Scholar] [CrossRef] [PubMed]
[47] Hwang, J.C., Peacker, B.L. and Hartman, R.I. (2025) Screening and Novel Diagnostic Technologies for Melanoma: An Update. Melanoma Management, 12, Article ID: 2536999. [Google Scholar] [CrossRef] [PubMed]